Immunosuppressants - Sweden

Sweden

In Sweden, the Immunosuppressants market is anticipated to witness a substantial growth in revenue, reaching a projected value of US$164.30m in 2024.
Looking ahead, the market is expected to exhibit a promising compound annual growth rate (CAGR 2024-2029) of 15.23%, leading to a market volume of US$333.80m by 2029.
It is noteworthy to mention that when compared globally, United States is projected to generate the highest revenue in the Immunosuppressants market, with an estimated value of US$35,470.00m in 2024.
Sweden's strong focus on research and development has positioned it as a leading market for innovative immunosuppressants.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for immunosuppressants in Sweden has been on the rise in recent years, driven by an aging population and increasing prevalence of chronic diseases.

Customer preferences: Patients in Sweden prefer immunosuppressants that have minimal side effects and are easy to administer. They also tend to prioritize drugs that have been clinically tested and approved by regulatory authorities.

Trends in the market: One of the major trends in the immunosuppressants market in Sweden is the increasing adoption of biologic drugs, which offer targeted treatment and better efficacy compared to traditional immunosuppressants. This trend is expected to continue in the coming years as more biologic drugs enter the market. Another trend is the growing popularity of immunosuppressants for the treatment of autoimmune diseases, such as rheumatoid arthritis and psoriasis.

Local special circumstances: Sweden has a well-developed healthcare system that provides universal coverage to its citizens. This has led to a high demand for immunosuppressants, as patients have access to these drugs through the public healthcare system. Additionally, the Swedish government heavily regulates drug prices, which has led to lower prices for immunosuppressants compared to other countries in Europe.

Underlying macroeconomic factors: Sweden has a high per capita income and a strong economy, which has enabled the government to invest in healthcare infrastructure and research. This has created a favorable environment for the development and adoption of new immunosuppressants. Additionally, the country has a high life expectancy and an aging population, which has led to an increase in the prevalence of chronic diseases that require immunosuppressant treatment.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.